(SOON) Sonova H - Ratings and Ratios
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012549785
SOON: Hearing Instruments, Cochlear Implants, Headphones, Hearables
Sonova Holding AG stands as a leader in the hearing care industry, addressing a critical need for millions worldwide. With a market capitalization of approximately 18 billion CHF, the companys size underscores its significant role in the market. The P/E ratio of 32.17 reflects investor confidence in its growth prospects, while the forward P/E of 23.26 hints at expected expansion.
The companys operations are divided into two key segments: Hearing Instruments and Cochlear Implants. Under the Hearing Instruments segment, Sonova offers a diverse range of products through brands like Phonak, Unitron, and Hansaton, including advanced hearing aids and audio devices. Their retail network, spanning brands such as AudioNova and Connect Hearing, provides comprehensive audiological services, enhancing their market reach and customer accessibility.
The Cochlear Implants segment, operating under Advanced Bionics, specializes in innovative implant solutions, catering to those with severe hearing loss. This segment is pivotal for long-term growth, driven by technological advancements and increasing awareness of cochlear implants.
Investors should note the P/S ratio of 4.99, indicating strong revenue per share, a positive indicator of the companys profitability. Sonovas commitment to innovation and extensive distribution network positions it as a leader in the hearing care industry, making it a compelling consideration for those invested in healthcare technology.
Additional Sources for SOON Stock
SOON Stock Overview
| Market Cap in USD | 17,161m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
SOON Stock Ratings
| Growth Rating | 24.5 |
| Fundamental | 78.1 |
| Dividend Rating | 47.5 |
| Rel. Strength | -7.29 |
| Analysts | - |
| Fair Price Momentum | 195.73 CHF |
| Fair Price DCF | 459.95 CHF |
SOON Dividends
| Dividend Yield 12m | 1.64% |
| Yield on Cost 5y | 2.58% |
| Annual Growth 5y | 7.67% |
| Payout Consistency | 86.1% |
SOON Growth Ratios
| Growth Correlation 3m | -98.1% |
| Growth Correlation 12m | 23.8% |
| Growth Correlation 5y | 27.3% |
| CAGR 5y | 6.67% |
| CAGR/Max DD 5y | 0.14 |
| Sharpe Ratio 12m | -0.96 |
| Alpha | -12.64 |
| Beta | 1.115 |
| Volatility | 28.95% |
| Current Volume | 302.8k |
| Average Volume 20d | 172.9k |
As of April 17, 2025, the stock is trading at CHF 230.90 with a total of 302,759 shares traded.
Over the past week, the price has changed by +1.27%, over one month by -14.07%, over three months by -24.00% and over the past year by -7.41%.
Yes, based on ValueRay Fundamental Analyses, Sonova H (SW:SOON) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 78.13 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SOON as of April 2025 is 195.73. This means that SOON is currently overvalued and has a potential downside of -15.23%.
Sonova H has no consensus analysts rating.
According to ValueRays Forecast Model, SOON Sonova H will be worth about 216.9 in April 2026. The stock is currently trading at 230.90. This means that the stock has a potential downside of -6.06%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 292.4 | 26.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 216.9 | -6.1% |